Molecular Diagnostics Dominated by Five Companies
|
By LabMedica International staff writers Posted on 17 Feb 2014 |
|
The latest analysis from Kalorama Information (New York City, NY, USA) finds that 5 companies currently dominate the molecular diagnostics market.
According to report, the 5 companies that currently own the majority of the molecular diagnostics (MD) market are Roche, Hologic, Qiagen, Becton Dickinson, and Abbott, and these alone were estimated to have earned 60% of revenues in the 5.5 billion MD market in 2013.
Top-tier companies are said to continue to dominate due to their global reach and multisegment participation. As in vitro diagnostics (IVD) in North America and Europe offer little growth opportunities for the vast number of tests, the top tier has invested in molecular and personalized medicine testing and has reinforced international connections. The report adds that while the names of the dominating players have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while leaders are seeing flatter revenues. For example, “Roche holds the number one market position but growth is slowing,” said Shara Rosen, author of the report. “Roche Diagnostics once earned close to double-digit revenue growth in its molecular test business. This has slowed in the last 2 years.”
The report said that IVD veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly, infectious disease tests. Meanwhile, Novartis has stepped out of blood screening to concentrate on other business units.
According to the report, IVD tests are being developed constantly and MD is becoming a go-to resource in clinical practice and is currently the faster-growing part of the diagnostics market.
These and additional findings are published in Kalorama’s "Molecular Diagnostics Six Month Update," the latest, extensive market analysis of the IVD segment, with a bias towards the more developed areas (North America and Western Europe). Given the amount of activity in test development and regulatory and reimbursement challenges, Kalorama focused this update on the last half of 2013.
Related Links:
Kalorama Information
Molecular Diagnostics Six Month Update
According to report, the 5 companies that currently own the majority of the molecular diagnostics (MD) market are Roche, Hologic, Qiagen, Becton Dickinson, and Abbott, and these alone were estimated to have earned 60% of revenues in the 5.5 billion MD market in 2013.
Top-tier companies are said to continue to dominate due to their global reach and multisegment participation. As in vitro diagnostics (IVD) in North America and Europe offer little growth opportunities for the vast number of tests, the top tier has invested in molecular and personalized medicine testing and has reinforced international connections. The report adds that while the names of the dominating players have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while leaders are seeing flatter revenues. For example, “Roche holds the number one market position but growth is slowing,” said Shara Rosen, author of the report. “Roche Diagnostics once earned close to double-digit revenue growth in its molecular test business. This has slowed in the last 2 years.”
The report said that IVD veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly, infectious disease tests. Meanwhile, Novartis has stepped out of blood screening to concentrate on other business units.
According to the report, IVD tests are being developed constantly and MD is becoming a go-to resource in clinical practice and is currently the faster-growing part of the diagnostics market.
These and additional findings are published in Kalorama’s "Molecular Diagnostics Six Month Update," the latest, extensive market analysis of the IVD segment, with a bias towards the more developed areas (North America and Western Europe). Given the amount of activity in test development and regulatory and reimbursement challenges, Kalorama focused this update on the last half of 2013.
Related Links:
Kalorama Information
Molecular Diagnostics Six Month Update
Gold Member
Hematology Analyzer
Medonic M32B
Gel Cards
DG Gel Cards
Human Estradiol Assay
Human Estradiol CLIA Kit
Latest Industry News
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
- Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation
- VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
- Werfen and VolitionRx Partner to Advance Diagnostic Testing for Antiphospholipid Syndrome
- Siemens Healthineers and Carna Health Partner to Advance Kidney Care Innovation
- Vircell Launches New Website for Molecular Control Products
- Tempus AI Acquires Digital Pathology Company Paige
- New Manual to Help Clinicians Better Diagnose and Treat Infection-Associated Chronic Illness
- WHO Releases Updated Guidance on Tuberculosis Diagnosis
- Pioneering Collaboration to Transform Pediatric Cancer Diagnostics and Research
- Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
Blood Protein Tests Could Identify Distinct Molecular Fingerprints of Multiple Diseases
Accurately distinguishing disease-related molecular changes from common biological variations has long been a challenge in clinical diagnostics, often leading to false alarms in blood test results.... Read more
Interstitial Lung Disease Test Could Identify Patients Before Symptoms Appear
Interstitial lung disease (ILD) is a group of chronic respiratory disorders that cause inflammation and scarring of lung tissue, often leading to irreversible damage and the need for lung transplants.... Read more
Hematology
view channel
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Luminescent Probe Measures Immune Cell Activity in Real Time
The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more
Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more
Microbiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read more
Pathology
view channel
New Imaging Tech to Improve Diagnosis and Treatment of Skin Cancers
Skin cancer is the most common malignancy worldwide, and accurately assessing tumor invasion or treatment response remains a major clinical challenge. Current imaging methods, such as confocal microscopy... Read more
Serially Testing Brain Tumor Samples Reveals Treatment Response in Glioblastoma Patients
Glioblastoma (GBM) is the most aggressive form of brain cancer, known for rapid growth, recurrence, and resistance to treatment. Understanding how tumors respond to therapy remains challenging since imaging... Read more
High-Accuracy Tumor Detection Method Offers Real-Time Surgical Guidance
Pancreatic neuroendocrine neoplasms (PNENs) are rare cancers that affect hormone-producing cells in the pancreas. Although uncommon, their incidence has been increasing, and surgery remains the only curative option.... Read more
Technology
view channel
Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
Rapid and sensitive detection of small extracellular vesicles (sEVs)—key biomarkers in cancer and organ health monitoring—remains challenging due to the need for multiple preprocessing steps and bulky... Read more
AI Algorithm Assesses Progressive Decline in Kidney Function
Chronic kidney disease (CKD) affects more than 700 million people worldwide and remains a major global health challenge. The condition often progresses silently, and many patients remain undiagnosed until... Read more
Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. What makes it particularly insidious is that flu viruses are contagious even before... Read more